ClearPoint Neuro Announces Promising Clinical Study Results for Prism Neuro Laser Therapy System in Brain Tumor Treatment

Reuters2025-10-08

<a href="https://laohu8.com/S/CLPT">ClearPoint Neuro</a> Announces Promising Clinical Study Results for Prism Neuro Laser Therapy System in Brain Tumor Treatment

ClearPoint Neuro Inc. has announced encouraging results from a Phase I-II clinical study evaluating the ClearPoint Prism Neuro Laser Therapy System for the treatment of primary and recurrent glioblastoma and grade 4 astrocytoma. The study, conducted at Skåne University Hospital in Lund, Sweden, included fourteen patients and assessed the safety, feasibility, and efficacy of the device. Findings indicated improved survival compared to matched open surgery controls and demonstrated a safe, feasible, and reproducible workflow with a median ablation time of 6.5 minutes. No device-related events or complications were reported. The results from this study will be presented at the 75th Annual Congress of Neurological Surgeons $(CNS)$ in Los Angeles, scheduled for October 13-15, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ClearPoint Neuro Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1084118) on October 07, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

1

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2573457993?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-08 04:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573457993","market":"us","top_or_hot":-1,"title":"ClearPoint Neuro Announces Promising Clinical Study Results for Prism Neuro Laser Therapy System in Brain Tumor Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CLPT\">ClearPoint Neuro</a> Announces Promising Clinical Study Results for Prism Neuro Laser Therapy System in Brain Tumor Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ClearPoint Neuro Inc. has announced encouraging results from a Phase I-II clinical study evaluating the ClearPoint Prism Neuro Laser Therapy System for the treatment of primary and recurrent glioblastoma and grade 4 astrocytoma. The study, conducted at Skåne University Hospital in Lund, Sweden, included fourteen patients and assessed the safety, feasibility, and efficacy of the device. Findings indicated improved survival compared to matched open surgery controls and demonstrated a safe, feasible, and reproducible workflow with a median ablation time of 6.5 minutes. No device-related events or complications were reported. The results from this study will be presented at the 75th Annual Congress of Neurological Surgeons <a href=\"https://laohu8.com/S/CNS\">$(CNS)$</a> in Los Angeles, scheduled for October 13-15, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ClearPoint Neuro Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1084118) on October 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ClearPoint Neuro Announces Promising Clinical Study Results for Prism Neuro Laser Therapy System in Brain Tumor Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClearPoint Neuro Announces Promising Clinical Study Results for Prism Neuro Laser Therapy System in Brain Tumor Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-08 04:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CLPT\">ClearPoint Neuro</a> Announces Promising Clinical Study Results for Prism Neuro Laser Therapy System in Brain Tumor Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ClearPoint Neuro Inc. has announced encouraging results from a Phase I-II clinical study evaluating the ClearPoint Prism Neuro Laser Therapy System for the treatment of primary and recurrent glioblastoma and grade 4 astrocytoma. The study, conducted at Skåne University Hospital in Lund, Sweden, included fourteen patients and assessed the safety, feasibility, and efficacy of the device. Findings indicated improved survival compared to matched open surgery controls and demonstrated a safe, feasible, and reproducible workflow with a median ablation time of 6.5 minutes. No device-related events or complications were reported. The results from this study will be presented at the 75th Annual Congress of Neurological Surgeons <a href=\"https://laohu8.com/S/CNS\">$(CNS)$</a> in Los Angeles, scheduled for October 13-15, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ClearPoint Neuro Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1084118) on October 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nNDL1spwZn:1","article_id":"2573457993","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573457993","pubTimestamp":1759868130,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ClearPoint Neuro Inc. has announced encouraging results from a Phase I-II clinical study evaluating the ClearPoint Prism Neuro Laser Therapy System for the treatment of primary and recurrent glioblastoma and grade 4 astrocytoma. The study, conducted at Skne University Hospital in Lund, Sweden, included fourteen patients and assessed the safety, feasibility, and efficacy of the device. Findings indicated improved survival compared to matched open surgery controls and demonstrated a safe, feasible, and reproducible workflow with a median ablation time of 6.5 minutes. No device-related events or complications were reported. The results from this study will be presented at the 75th Annual Congress of Neurological Surgeons  in Los Angeles, scheduled for October 13-15, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","CLPT":"ClearPoint Neuro, Inc."},"translate_title":"ClearPoint Neuro宣布Prism神经激光治疗系统在脑肿瘤治疗中的有希望的临床研究结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLPT":0.9},"content_text":"ClearPoint Neuro Announces Promising Clinical Study Results for Prism Neuro Laser Therapy System in Brain Tumor Treatment\n    \n\n        ClearPoint Neuro Inc. has announced encouraging results from a Phase I-II clinical study evaluating the ClearPoint Prism Neuro Laser Therapy System for the treatment of primary and recurrent glioblastoma and grade 4 astrocytoma. The study, conducted at Skåne University Hospital in Lund, Sweden, included fourteen patients and assessed the safety, feasibility, and efficacy of the device. Findings indicated improved survival compared to matched open surgery controls and demonstrated a safe, feasible, and reproducible workflow with a median ablation time of 6.5 minutes. No device-related events or complications were reported. The results from this study will be presented at the 75th Annual Congress of Neurological Surgeons $(CNS)$ in Los Angeles, scheduled for October 13-15, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ClearPoint Neuro Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1084118) on October 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2573457993","isCrawlerRequest":true}